Matching articles for "Pantoprazole"
Issue 1650 · May 16, 2022 Free
Addendum: Dexlansoprazole for GERD

A reader commented that our recent article on Drugs for GERD and Peptic Ulcer Disease did not include enough information on dexlansoprazole ( Dexilant , and generics), a proton pump inhibitor (PPI) claimed to…

Med Lett Drugs Ther. 2022 May 16; 64(1650):79-80
A reader commented that our recent article on Drugs for GERD and Peptic Ulcer Disease did not include enough information on dexlansoprazole ( Dexilant , and generics), a proton pump inhibitor (PPI) claimed to provide "all-day and all-night relief from heartburn". Dexlansoprazole recently became available generically, but it is much more expensive than other generic PPIs.
Issue 1647 · April 4, 2022
Drugs for GERD and Peptic Ulcer Disease

Gastroesophageal reflux disease (GERD) is the most common GI condition encountered in the outpatient setting; it affects about 20% of people in the US.

Med Lett Drugs Ther. 2022 Apr 4; 64(1647):49-56
Gastroesophageal reflux disease (GERD) is the most common GI condition encountered in the outpatient setting; it affects about 20% of people in the US.
Issue 1647 · April 4, 2022
Comparison Table: H2-Receptor Antagonists and PPIs (online only)

View the Comparison Table: H2-Receptor Antagonists and PPIs

Med Lett Drugs Ther. 2022 Apr 4; 64(1647):e56-7
View the Comparison Table: H2-Receptor Antagonists and PPIs
Issue 1538 · January 15, 2018
Drugs for GERD and Peptic Ulcer Disease

Gastroesophageal reflux disease (GERD) is the most frequent GI condition encountered in the outpatient setting; it affects about 20% of the US population. Heartburn and regurgitation are the classic symptoms…

Med Lett Drugs Ther. 2018 Jan 15; 60(1538):9-16
Gastroesophageal reflux disease (GERD) is the most frequent GI condition encountered in the outpatient setting; it affects about 20% of the US population. Heartburn and regurgitation are the classic symptoms of GERD.
Issue 1538 · January 15, 2018
Comparison Table: Drugs for GERD and Peptic Ulcer Disease (online only)

View the Comparison Table: Drugs for GERD and Peptic Ulcer Disease

Med Lett Drugs Ther. 2018 Jan 15; 60(1538):e16-8
View the Comparison Table: Drugs for GERD and Peptic Ulcer Disease
Issue 1527 · August 14, 2017
Safety of Long-Term PPI Use

Proton pump inhibitors (PPIs), which are used for treatment of gastroesophageal reflux disease (GERD) and for prevention of upper gastrointestinal adverse effects caused by NSAIDs and aspirin, are one of the…

Med Lett Drugs Ther. 2017 Aug 14; 59(1527):131-3
Proton pump inhibitors (PPIs), which are used for treatment of gastroesophageal reflux disease (GERD) and for prevention of upper gastrointestinal adverse effects caused by NSAIDs and aspirin, are one of the most commonly prescribed classes of drugs in the US. All PPIs are similarly effective and generally well tolerated, but their long-term use has been associated with a number of safety concerns. Recommendations addressing these concerns have recently been published.
Issue 1525 · July 17, 2017
Drugs for Helicobacter pylori Infection

About 50% of the world’s population is infected with Helicobacter pylori . These gastric bacteria can cause chronic inflammation and have been associated with development of gastritis, peptic ulcer disease,…

Med Lett Drugs Ther. 2017 Jul 17; 59(1525):113-7
About 50% of the world’s population is infected with Helicobacter pylori . These gastric bacteria can cause chronic inflammation and have been associated with development of gastritis, peptic ulcer disease, gastric adenocarcinoma, and gastric mucosa-associated lymphoid tissue (MALT) lymphoma. Eradication of H. pylori can promote gastric healing, prevent recurrence of duodenal and gastric ulcers, and reduce the incidence of gastric cancer. Guidelines for treatment of H. pylori infection were updated recently.
Issue 1509 · December 5, 2016 Free
In Brief: PPIs and Torsades de Pointes

Therapeutics (AZCERT) has recently added the proton pump inhibitors (PPIs) omeprazole ( Prilosec , and others), esomeprazole ( Nexium , and others), lansoprazole ( Prevacid , and others), and pantoprazole (…

Med Lett Drugs Ther. 2016 Dec 5; 58(1509):153
Therapeutics (AZCERT) has recently added the proton pump inhibitors (PPIs) omeprazole ( Prilosec , and others), esomeprazole ( Nexium , and others), lansoprazole ( Prevacid , and others), and pantoprazole ( Protonix , and generics) to its lists of Drugs with Conditional Risk of Torsades de Pointes (TdP) and Drugs to Avoid in Patients with Congenital Long QT Syndrome. 1 PPIs do not directly cause prolongation of the QT interval, but they can cause hypomagnesemia, which is often accompanied by hypocalcemia and hypokalemia and can result in cardiac repolarization disturbances such as QT interval prolongation. 2 Reports have described cases of QT interval prolongation and TdP associated with severe PPI-induced hypomagnesemia. 3,4 TdP has also been reported in patients taking a PPI concomitantly with drugs that directly prolong the QT interval. 5,6 The newer PPIs dexlansoprazole (Dexilant) and rabeprazole ( Aciphex , and generics) have not been linked to QT interval prolongation or TdP to date, but they have been associated with hypomagnesemia. Serum magnesium levels should be monitored periodically in patients taking a PPI for an extended period of time (>2 weeks). If possible, extended PPI therapy should be avoided in patients who require treatment with drugs that carry a known risk of TdP 7 and in those with long QT syndrome. If extended PPI therapy must be used with a drug that prolongs the QT interval, close monitoring of magnesium levels and the QT interval is recommended. AZCERT. New drugs added to CredibleMeds drugs lists. November 2, 2016. Available at: www.crediblemeds.org. Accessed November 22, 2016. In brief: PPIs and hypomagnesemia. Med Lett Drugs Ther 2011; 53:25. EJ Hoorn et al. A case series of proton pump inhibitor-induced hypomagnesemia. Am J Kidney Dis 2010; 56:112. BA Hansen and Ø Bruserud. Hypomagnesemia as a potentially life-threatening adverse effect of omeprazole. Oxf Med Case Reports 2016; 2016:147. H Asajima et al. Lansoprazole precipitated QT prolongation and torsade de pointes associated with disopyramide. Eur J Clin Pharmacol 2012; 68:331. JN Bibawy et al. Pantoprazole (proton pump inhibitor) contributing to torsades de pointes storm. Circ Arrhythm Electrophysiol 2013; 6:e17. RL Woosley and KA Romero. QT drugs list. Available at: www.crediblemeds. org. Accessed November 22, 2016. Download complete U.S. English article
Issue 1471 · June 22, 2015
Which PPI?

An article published in the New York Times on May 1, 2015 listed the 10 drugs on which Medicare Part D spent the most in 2013. The most costly ($2.53 billion) was the proton pump inhibitor (PPI) Nexium…

Med Lett Drugs Ther. 2015 Jun 22; 57(1471):91
An article published in the New York Times on May 1, 2015 listed the 10 drugs on which Medicare Part D spent the most in 2013. The most costly ($2.53 billion) was the proton pump inhibitor (PPI) Nexium (esomeprazole magnesium), which has recently become available generically.
Issue 1454 · October 27, 2014
Antithrombotic Drugs

Antiplatelet drugs are the drugs of choice for prevention and treatment of arterial thrombosis. Anticoagulants are the drugs of choice for prevention and treatment of venous thromboembolism and for prevention…

Med Lett Drugs Ther. 2014 Oct 27; 56(1454):103-8
Antiplatelet drugs are the drugs of choice for prevention and treatment of arterial thrombosis. Anticoagulants are the drugs of choice for prevention and treatment of venous thromboembolism and for prevention of cardioembolic events in patients with atrial fibrillation.
Issue 1447 · July 21, 2014 Free
In Brief: Esomeprazole Strontium

The FDA has approved the proton pump inhibitor (PPI) esomeprazole strontium for use in adults for the same indications as esomeprazole magnesium (Nexium) : treatment of gastroesophageal reflux disease (GERD),…

Med Lett Drugs Ther. 2014 Jul 21; 56(1447):64
The FDA has approved the proton pump inhibitor (PPI) esomeprazole strontium for use in adults for the same indications as esomeprazole magnesium (Nexium) : treatment of gastroesophageal reflux disease (GERD), prevention of NSAID-induced gastric ulcers, eradication of Helicobacter pylori , and treatment of pathological hypersecretory conditions. It was first marketed in December 2013 as a branded drug (Esomeprazole Strontium) and a month later as a generic drug. Strontium is incorporated into bone. It is not recommended for use in children or during pregnancy because of the absence of safety data in those populations. Use of esomeprazole strontium is not recommended for patients with severe renal impairment. Esomeprazole strontium is the seventh PPI to become available as a single agent in the US. No new clinical trials were required for its approval, which was based on earlier clinical trials with esomeprazole magnesium. All of the PPIs appear to be equally effective. 1 Drugs for peptic ulcer disease and GERD. Treat Guidel Med Lett 2014; 12:25. Download complete U.S. English article
Issue 140 · April 1, 2014
Drugs for Peptic Ulcer Disease and GERD

H2-RECEPTOR ANTAGONISTS (H2RAs) — Currently available H2RAs are listed in Table 1. These drugs inhibit the action of histamine at the H2-receptor of the gastric parietal cell, decreasing basal acid secretion…

Treat Guidel Med Lett. 2014 Apr; 12(140):25-30
H2-RECEPTOR ANTAGONISTS (H2RAs) — Currently available H2RAs are listed in Table 1. These drugs inhibit the action of histamine at the H2-receptor of the gastric parietal cell, decreasing basal acid secretion and, to a lesser degree, food-stimulated acid secretion. All H2RAs are about equally effective for treatment of PUD and GERD. H2RAs are faster acting than PPIs in relieving symptoms of dyspepsia or GERD, but they are not as effective as PPIs in relieving symptoms or in healing erosive esophagitis. Repeated administration of H2RAs leads to pharmacologic tolerance and has been associated with the development of new dyspeptic symptoms. Rebound acid hypersecretion can occur after stopping H2RAs.
Issue 109 · September 1, 2011
Drugs for Peptic Ulcer Disease and GERD

Peptic ulcer disease (PUD) is usually caused by nonsteroidal anti-inflammatory drugs (NSAIDs) or by infection with Helicobacter pylori . Gastroesophageal reflux disease (GERD) can be caused by transient lower…

Treat Guidel Med Lett. 2011 Sep; 9(109):55-60
Peptic ulcer disease (PUD) is usually caused by nonsteroidal anti-inflammatory drugs (NSAIDs) or by infection with Helicobacter pylori . Gastroesophageal reflux disease (GERD) can be caused by transient lower esophageal sphincter relaxation, reduced lower esophageal sphincter tone, hiatal hernia, delayed gastric emptying or hormonal changes due to pregnancy. Acid suppressive therapy is the cornerstone of management for both PUD and GERD.
Issue 1352 · November 29, 2010 Free
In Brief: Clopidogrel and Omeprazole

Use of a proton pump inhibitor (PPI) to protect against gastrointestinal (GI) bleeding in patients taking the antiplatelet agent clopidogrel (Plavix) may interfere with the activation of clopidogrel and…

Med Lett Drugs Ther. 2010 Nov 29; 52(1352):93
Use of a proton pump inhibitor (PPI) to protect against gastrointestinal (GI) bleeding in patients taking the antiplatelet agent clopidogrel (Plavix) may interfere with the activation of clopidogrel and diminish its antiplatelet effect, increasing the risk of cardiovascular events. 1 A randomized, placebo-controlled trial (COGENT) has found that use of the PPI omeprazole in patients taking clopidogrel in addition to aspirin decreased the incidence of GI bleeding without increasing the risk of a cardiovascular event, but the number of cardiovascular events was small and the formulation of omeprazole was atypical. 2 The FDA in the same issue of the same journal cautioned against concluding from the results of COGENT that concurrent use of clopidogrel and omeprazole is safe. 3 To some extent, all PPIs reduce the enzymatic activity of CYP2C19, which is thought to be mainly responsible for the bioactivation of clopidogrel. Omeprazole is a strong inhibitor of CYP2C19; pantoprazole ( Protonix , and others) appears to have less effect on CYP2C19 and not to attenuate the antiplatelet effect of clopidogrel. 4-6 Medical Letter consultants believe that patients at risk for upper GI bleeding who take clopidogrel should also take a PPI, but not omeprazole. Until more data become available on other PPIs, pantoprazole would be a reasonable choice. 1. PPI interactions with clopidogrel revisited. Med Lett Drugs Ther 2009; 51:13. 2. DL Bhatt et al. Clopidogrel with or without omeprazole in coronary artery disease. N Engl J Med 2010; 363:1909. 3. MR Southworth and R Temple. Interaction of clopidogrel and omeprazole. N Engl J Med 2010; 363:1977. 4. DJ Angiolillo et al. Differential effects of omeprazole and pantoprazole on the pharmacodynamics and pharmacokinetics of clopidogrel in healthy subjects: randomized, placebo-controlled, crossover comparison studies. Clin Pharmacol Ther 2010; Sept 15 epub. 5. T Cuisset et al. Comparison of omeprazole and pantoprazole influence on a high 150-mg clopidogrel maintenance dose: the PACA (Proton Pump Inhibitors And Clopidogrel Association) prospective randomized study. J Am Coll Cardiol 2009; 54:1149. 6. H Neubaurer et al. Pantoprazole does not influence the antiplatelet effect of clopidogrel – a whole blood aggregometry study after coronary stenting. J Cardiovasc Pharmacol 2010; 56:91. Download U.S. English
Issue 1333 · March 8, 2010 Free
Primary Prevention of Ulcers in Patients Taking Aspirin or NSAIDs

Aspirin and other nonsteroidal anti-inflammatory drugs (NSAIDs) are common causes of peptic ulcer disease. Patients infected with Helicobacter pylori who take aspirin or another NSAID have an especially high…

Med Lett Drugs Ther. 2010 Mar 8; 52(1333):17-9
Aspirin and other nonsteroidal anti-inflammatory drugs (NSAIDs) are common causes of peptic ulcer disease. Patients infected with Helicobacter pylori who take aspirin or another NSAID have an especially high risk. Drugs that have been tried for prevention of ulcers in patients taking NSAIDs including H 2 -receptor antagonists, proton pump inhibitors (PPIs), aluminum- or magnesium-containing antacids, the prostaglandin misoprostol ( Cytotec , and others), and antibiotics to eradicate H. pylori . Click here to view the free full article.
Issue 1306 · February 23, 2009
PPI Interactions with Clopidogrel Revisted

Current guidelines recommend use of a proton pump inhibitor (PPI) to decrease the risk of gastrointestinal bleeding in patients taking clopidogrel (Plavix) with aspirin. A recent issue of The Medical Letter…

Med Lett Drugs Ther. 2009 Feb 23; 51(1306):13-4
Current guidelines recommend use of a proton pump inhibitor (PPI) to decrease the risk of gastrointestinal bleeding in patients taking clopidogrel (Plavix) with aspirin. A recent issue of The Medical Letter considered whether omeprazole ( Prilosec , and others) or other PPIs could interfere with the antiplatelet effect of clopidogrel. The conclusion was that patients taking both drugs should probably continue to do so until more data became available. Several new publications require reconsideration of that recommendation.
Issue 1303 · January 12, 2009
PPI Interactions with Clopidogrel

Clopidogrel (Plavix) , which prevents arterial thrombosis by inhibiting platelet activation, is commonly prescribed (usually with aspirin) for months after acute coronary syndromes and stent implantation. It…

Med Lett Drugs Ther. 2009 Jan 12; 51(1303):2-3
Clopidogrel (Plavix) , which prevents arterial thrombosis by inhibiting platelet activation, is commonly prescribed (usually with aspirin) for months after acute coronary syndromes and stent implantation. It may also, however, increase the risk of bleeding. Therefore, a proton pump inhibitor (PPI) such as omeprazole (Prilosec, and others) is often given concurrently to decrease the risk of gastrointestinal (GI) bleeding. Some reports have suggested that omeprazole may interfere with the antiplatelet effect of clopidogrel.
Issue 72 · August 1, 2008
Treatment of Peptic Ulcers and GERD

Peptic ulcers caused by treatment with nonsteroidal anti-inflammatory drugs (NSAIDs) are mainly gastric ulcers. Most duodenal and other gastric ulcers are caused by the gram-negative bacillus Helicobacter…

Treat Guidel Med Lett. 2008 Aug; 6(72):55-60
Peptic ulcers caused by treatment with nonsteroidal anti-inflammatory drugs (NSAIDs) are mainly gastric ulcers. Most duodenal and other gastric ulcers are caused by the gram-negative bacillus Helicobacter pylori. Gastroesophageal reflux disease (GERD) is caused by gastric acid reflux into the esophagus. Drugs that suppress gastric acid production are the primary treatment for GERD and peptic ulcers.
Issue 1255 · February 26, 2007
Proton Pump Inhibitors for GERD in Children

A recent advertisement for the proton pump inhibitor (PPI) lansoprazole ( Prevacid - TAP) suggests that children who cough at night, complain of abdominal pain, refuse to eat, or have a bad taste in their…

Med Lett Drugs Ther. 2007 Feb 26; 49(1255):17-8
A recent advertisement for the proton pump inhibitor (PPI) lansoprazole ( Prevacid - TAP) suggests that children who cough at night, complain of abdominal pain, refuse to eat, or have a bad taste in their mouths may all have gastroesophageal reflux disease (GERD). A Bunny's Tummy Trouble , a children's book about GERD published by TAP, is now available as a patient handout in pediatricians' waiting rooms. The use of acid-suppressive drugs in infants and children has increased markedly in recent years and many of these drugs are now available in child-friendly formulations. A table in the article lists some of the drugs used to treat GERD in children.
Issue 1215 · August 15, 2005
AmpliChip CYP450 Test

The FDA recently cleared the AmpliChip CYP450 Test (Roche), which analyzes blood-derived DNA to detect genetic variations in the activity of cytochrome P450 (CYP) enzymes CYP2D6 and CYP2C19 and determines the…

Med Lett Drugs Ther. 2005 Aug 15; 47(1215):71-2
The FDA recently cleared the AmpliChip CYP450 Test (Roche), which analyzes blood-derived DNA to detect genetic variations in the activity of cytochrome P450 (CYP) enzymes CYP2D6 and CYP2C19 and determines the metabolizer status of the patient. The test is intended to help guide clinicians in prescribing individualized drug therapy. About 25% of all drugs, including many antidepressants and antipsychotics, are substrates of either CYP2D6 or CYP2C19. The test is being promoted initially to psychiatrists.
Issue 18 · February 1, 2004
Drugs for Peptic Ulcers

Most peptic ulcers not caused by nonsteroidal anti-inflammatory drugs (NSAIDs) are associated with infection of the gastric mucosa by the gram-negative bacilli Helicobacter pylori . The majority of…

Treat Guidel Med Lett. 2004 Feb; 2(18):7-12
Most peptic ulcers not caused by nonsteroidal anti-inflammatory drugs (NSAIDs) are associated with infection of the gastric mucosa by the gram-negative bacilli Helicobacter pylori . The majority of NSAID-related ulcers are gastric. H. pylori infection causes both duodenal and gastric ulcers. Eradication of H. pylori promotes healing and markedly decreases recurrence of both duodenal and gastric ulcers (A Shiotamni and DY Graham, Med Clin North Am 2002; 86:1447; FKL Chan and WK Leung, Lancet 2002; 360:933). The first step in the management of peptic ulcers is the diagnosis and treatment of H. pylori .
Issue 1158 · June 8, 2003
Drug Interactions

Changes caused by one drug in the absorption, distribution, metabolism or excretion of another may lead to a pharmacokinetic adverse drug interaction (DN Juurlink et al, JAMA 2003; 289:1652). Additive drug…

Med Lett Drugs Ther. 2003 Jun 8; 45(1158):46-8
Changes caused by one drug in the absorption, distribution, metabolism or excretion of another may lead to a pharmacokinetic adverse drug interaction (DN Juurlink et al, JAMA 2003; 289:1652). Additive drug interactions, such as vasodilation caused by both sildenafil (Viagra) and nitrates, can also have adverse effects.
Issue 1129 · April 29, 2002
Pantoprazole IV (Protonix IV)

An IV formulation of pantoprazole sodium ( Protonix IV - Wyeth-Ayerst), a benzimidazole proton pump inhibitor (PPI), has been approved by the FDA for short-term treatment of Zollinger-Ellison Syndrome (ZES)…

Med Lett Drugs Ther. 2002 Apr 29; 44(1129):41-2
An IV formulation of pantoprazole sodium ( Protonix IV - Wyeth-Ayerst), a benzimidazole proton pump inhibitor (PPI), has been approved by the FDA for short-term treatment of Zollinger-Ellison Syndrome (ZES) and gastroesophageal reflux disease (GERD) in patients who cannot take oral drugs. Pantoprazole is the first PPI to be approved for IV use in the US.
Issue 1103 · April 30, 2001
Esomeprazole (Nexium)

Esomeprazole magnesium (Nexium - AstraZeneca), the S-isomer of omeprazole (Prilosec) , is the fifth benzimidazole proton pump inhibitor to become available in the United States. Omeprazole, which was the…

Med Lett Drugs Ther. 2001 Apr 30; 43(1103):36-7
Esomeprazole magnesium (Nexium - AstraZeneca), the S-isomer of omeprazole (Prilosec) , is the fifth benzimidazole proton pump inhibitor to become available in the United States. Omeprazole, which was the first, is going off patent this year.
Issue 1084 · August 7, 2000 Free
Pantoprazole: A Clarification

The Medical Letter article on pantoprazole (July 24, 2000) stated that, according to Medical Letter consultants, pantoprazole tablets, like rabeprazole tablets (Aciphex) , can be crushed and administered…

Med Lett Drugs Ther. 2000 Aug 7; 42(1084):72
The Medical Letter article on pantoprazole (July 24, 2000) stated that, according to Medical Letter consultants, pantoprazole tablets, like rabeprazole tablets (Aciphex) , can be crushed and administered through a feeding tube. The article should have specified that this can only be done through a feeding tubes placed distal to the stomach because all proton pump inhibitors are inactivated by gastric acid. The labeling of pantoprazole and rabeprazole advises against crushing the tablets because oral administration is assumed and both drugs are formulated to prevent inactivation in the stomach.
Issue 1083 · July 24, 2000
Pantroprazole (Protonix)

Pantoprazole, the fourth benzimidazole proton pump inhibitor to become available in the United States, has been marketed for short-term oral treatment of erosive gastroesophageal reflux disease (GERD).

Med Lett Drugs Ther. 2000 Jul 24; 42(1083):65-6
Pantoprazole, the fourth benzimidazole proton pump inhibitor to become available in the United States, has been marketed for short-term oral treatment of erosive gastroesophageal reflux disease (GERD).